Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.47 |
| ▸ | PDE4A | P27815 | 4/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.39 |
| ▸ | TNF | P01375 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19601307 | 0.94 | LMNA (0.48) | LMNASMN1; SMN2POLBRXFP1PDE4A | |
| SCHEMBL17682127 | 0.87 | LMNA (0.62) | LMNASMN1; SMN2POLBRXFP1PDE4A | |
| SCHEMBL28415031 | 0.85 | LMNA (0.60) | LMNASMN1; SMN2POLBRXFP1PDE4A | |
| SCHEMBL28870869 | 0.83 | TNF (0.61) | LMNASMN1; SMN2POLBRXFP1PDE4A | |
| SCHEMBL17682120 | 0.82 | ADORA2B (0.58) | LMNASMN1; SMN2RXFP1PDE4ACYP1A2 | |
| SCHEMBL17682218 | 0.81 | LMNA (0.54) | LMNASMN1; SMN2POLBRXFP1PDE4A | |
| Xanthinol SCHEMBL121656 | 0.81 | LMNA (0.73) | LMNASMN1; SMN2POLBRXFP1ADORA2B | |
| SCHEMBL17682157 | 0.80 | PDE4A (0.57) | LMNASMN1; SMN2POLBRXFP1PDE4A | |
| SCHEMBL10346500 | 0.78 | LMNA (0.65) | LMNASMN1; SMN2POLBRXFP1PDE4A | |
| SCHEMBL18819566 | 0.77 | LMNA (0.63) | LMNASMN1; SMN2POLBRXFP1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49128-E1 | Hydroxyl purine compounds and applications thereof | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2022-07-12 | — | — | US | disclosed |
| US-20170326149-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-11-16 | — | — | US | disclosed |
| US-20170326149-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-11-16 | — | — | US | disclosed |
| EP-3205652-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | Medshine Discovery Inc. (CN) | 2017-08-16 | — | — | EP | disclosed |
| WO-2017071606-A1 | MEDICAL USE OF HYDROXYL PURINE COMPOUND | 南京明德新药研发股份有限公司 | 2017-05-04 | — | — | WO | disclosed |
| WO-2016054971-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | 南京明德新药研发股份有限公司 | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170326149-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | PNP, PDE2A, PDE7A | LMNA 2616/4885SMN1; SMN2 1807/4885POLB 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.